Navigation Links
Cobalis Expects to Report Phase III Top-Line Results in May

certainties relating to securing funding for ongoing operations including clinical trials, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the development of competing products by our competitors; uncertainties related to the Company's dependence on third parties and partners; and those risks described in our quarterly report on Form 10-QSB filed with the SEC on February 20, 2007.

Contact

Jaffoni & Collins Incorporated
David Collins or Steven Hecht, 212-835-8500
CLSC@jcir.com


'"/>




Page: 1 2

Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cobalis Expects Report Phase III Top Line Results May
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken ...ADHD within one week, PHILADELPHIA, Oct. 7 /PRNew...HPGY), the global specialty biopharmaceutical comp... September issue of the Journal of,Clinical Psychi...ed,Attention Deficit Hyperactivity Disorder (ADHD)...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sci...ire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. (...Inc. (NYSE: FRX ) today announced the presentatio...lotide,s safety and efficacy in 420 patients with,.... Analysis of the data,indicates that once- daily ...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aero... safety data from a Phase I trial of its Aerovant,...ty with no evidence of,local irritancy following a..., This 10 mg dose will be the highest of three do...ging study, which is scheduled to begin early,next...
(Date:10/7/2008)... 125 Patient, Prospective Randomized Placebo-Contr...Significant Improved Overall Survival., MOUNTAIN ...unoTherapeutics has now evaluated the mature Phase...ine candidate PROSTVAC(TM) that had been,obtained ...he National,Cancer Institute (NCI) in the US., Th...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 1Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 10Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 1Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 2Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 3Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 4Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 5Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 6ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 1ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 2Gender bias may affect care of people with osteoarthritis study finds 13976 1Gender bias may affect care of people with osteoarthritis study finds 13976 2
...7 - Novelos,Therapeutics, Inc. (OTCBB: NVLT), a bi... of therapeutics to treat cancer and,hepatitis, to...na-Farber/Partners Cancer Care (DF/PCC) Phase 2 tr...platinum-resistant ovarian,cancer patients. To dat...or response (assessed at least after 8 weeks / 2,c...
...m versus placebo: - 25,/ - 13 mm Hg (systolic / di...n vaccine dose and induced,antiangiotensin II anti... the Seventeenth European,Meeting on Hypertension ... and MILAN, Italy, June 17, 2007 -,Cytos Biotechno...ta,on its hypertension vaccine CYT006-AngQb at the...
Other Medicine Technology:Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 2Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...studies have suggested that drinking a lot of coff...h weight and may result in miscarriage or prematur...rs finds that there is no indication of a link bet...egnancy outcome. The study began with the recrui...
...has okayed the issue of compulsory licenses for in...,// a move, not likely to sit well with pharmaceut...onfirmed that the laws are in place and are effect..., the drugs are meant for treating HIV-AIDS and he...
...s at UC Irvine have discovered that learning appea...at are the hallmarks of Alzheimer's disease.// The...ir minds active, can help delay the onset of this ...s in the Jan. 24 issue of the Journal of Neuroscie...
...y of Miami researchers report that supplements of ...progression of HIV. // Deficiencies in selenium h...nce suggests that supplements of the nutrient can ... the researchers report in the Jan. 22 issue of th...
Other Medicine News:Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2Health News:Selenium Supplements May Slow Progression of HIV: Report 2Health News:Selenium Supplements May Slow Progression of HIV: Report 3
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: